These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 36765583)

  • 1. Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.
    Ma J; Bo Z; Zhao Z; Yang J; Yang Y; Li H; Yang Y; Wang J; Su Q; Wang J; Chen K; Yu Z; Wang Y; Chen G
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis prediction and risk stratification of transarterial chemoembolization or intraarterial chemotherapy for unresectable hepatocellular carcinoma based on machine learning.
    Liu W; Wei R; Chen J; Li Y; Pang H; Zhang W; An C; Li C
    Eur Radiol; 2024 Aug; 34(8):5094-5107. PubMed ID: 38291256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of Early Treatment Response to Initial Conventional Transarterial Chemoembolization Therapy for Hepatocellular Carcinoma by Machine-Learning Model Based on Computed Tomography.
    Dong Z; Lin Y; Lin F; Luo X; Lin Z; Zhang Y; Li L; Li ZP; Feng ST; Cai H; Peng Z
    J Hepatocell Carcinoma; 2021; 8():1473-1484. PubMed ID: 34877267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive model and risk analysis for peripheral vascular disease in type 2 diabetes mellitus patients using machine learning and shapley additive explanation.
    Liu L; Bi B; Cao L; Gui M; Ju F
    Front Endocrinol (Lausanne); 2024; 15():1320335. PubMed ID: 38481447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
    Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
    J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma.
    Ma KP; Fu JX; Duan F; Wang MQ
    World J Gastrointest Oncol; 2024 Apr; 16(4):1236-1247. PubMed ID: 38660650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of machine learning model in predicting the likelihood of blood transfusion after hip fracture surgery.
    Chen X; Pan J; Li Y; Tang R
    Aging Clin Exp Res; 2023 Nov; 35(11):2643-2656. PubMed ID: 37733228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of the development of acute kidney injury following cardiac surgery by machine learning.
    Tseng PY; Chen YT; Wang CH; Chiu KM; Peng YS; Hsu SP; Chen KL; Yang CY; Lee OK
    Crit Care; 2020 Jul; 24(1):478. PubMed ID: 32736589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical-radiomics predictors to identify the suitability of transarterial chemoembolization treatment in intermediate-stage hepatocellular carcinoma: A multicenter study.
    Wang DD; Zhang JF; Zhang LH; Niu M; Jiang HJ; Jia FC; Feng ST
    Hepatobiliary Pancreat Dis Int; 2023 Dec; 22(6):594-604. PubMed ID: 36456428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.
    Zhao S; Zhou M; Wang P; Yang J; Zhang D; Yin F; Song P
    Technol Cancer Res Treat; 2022; 21():15330338221133640. PubMed ID: 36259214
    [No Abstract]   [Full Text] [Related]  

  • 11. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
    Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
    Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Risk Prediction Model for Physical Restraints Among Older Chinese Adults in Long-term Care Facilities: Machine Learning Study.
    Wang J; Chen H; Wang H; Liu W; Peng D; Zhao Q; Xiao M
    J Med Internet Res; 2023 Apr; 25():e43815. PubMed ID: 37023416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study.
    Zhang JX; Chen YX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
    Hepatol Res; 2022 Sep; 52(9):794-803. PubMed ID: 35698267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An interpretable machine learning model based on contrast-enhanced CT parameters for predicting treatment response to conventional transarterial chemoembolization in patients with hepatocellular carcinoma.
    Zhang L; Jin Z; Li C; He Z; Zhang B; Chen Q; You J; Ma X; Shen H; Wang F; Wu L; Ma C; Zhang S
    Radiol Med; 2024 Mar; 129(3):353-367. PubMed ID: 38353864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma.
    Long J; Liu L; Yang X; Lu X; Qin L
    Pak J Med Sci; 2023; 39(6):1847-1852. PubMed ID: 37936761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.
    Cao F; Yang Y; Si T; Luo J; Zeng H; Zhang Z; Feng D; Chen Y; Zheng J
    Front Oncol; 2021; 11():783480. PubMed ID: 34988019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Efficacy and Safety of Transarterial Chemoembolization with or without Lenvatinib for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score-Matched Analysis.
    Chen YX; Zhang JX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
    J Hepatocell Carcinoma; 2022; 9():685-694. PubMed ID: 35937909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of lenvatinib plus transarterial chemoembolization in combination with PD-1 antibody in treatment of unresectable recurrent hepatocellular carcinoma: a case series report.
    Mu C; Shen J; Zhu X; Peng W; Zhang X; Wen T
    Front Oncol; 2023; 13():1096955. PubMed ID: 37260972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib in combination with transarterial chemoembolization vs. sorafenib in combination with transarterial chemoembolization for unresectable hepatocellular carcinoma: A network meta‑analysis.
    Li Y; Liu X; Liu J; Yang L; Wei S; Li J; Gan H; Ma T; Yi P
    Oncol Lett; 2024 Aug; 28(2):347. PubMed ID: 38872858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.